Zynex, Inc.

good afternoon ladies and gentlemen and welcome to the zynex third quarter 2023 earnings conference call at this time all participants are in a listen only mode should you need assistance please signal a conference specialist by pressing star then zero on your telephone keypad a question and answer session will follow the formal presentation as a reminder this conference is being recorded i would now like to turn the conference over to quinn Kalanen from MZ North America.

Thank you, Operator, and good afternoon, everyone. Earlier today, Zynex released financial results for the third quarter ending September 30, 2023. A copy of the press release is available on the company's website. Joining me on today's call are Thomas Sangard, Chairman, President, and Chief Executive Officer, Dan Moorhead, Chief Financial Officer, Anna Lusak, Chief Operating Officer, and Donald Gregg. President of Zynex Monitoring Solutions. Before we begin, I'd like to remind you that during this conference call, the company will make projections and forward-looking statements regarding future events. We encourage you to review the company's past and future filings with the SEC, including without limitation the company's 2022 Form 10-K and subsequent Form 10-Qs, which identify the specific factors that may cause actual results or events to differ materially from those described in these forward-looking statements. These factors may include, without limitation, statements regarding product development, product potential, the regulatory environment, sales and marketing strategies, capital resources, or operating performance. With that, I'll now turn the call over to Thomas.

Thanks, Quinn, and good afternoon, everyone. Thank you for joining us today for our third quarter 2023 earnings call. The third quarter was highlighted by ongoing revenue momentum, leading us to our 10th consecutive quarter of profitability and six-quarter record high order numbers. We once again received the highest number of prescriptions in the company's history, beating our previous record and celebrated our one millionth patient treated since our founder, Sinex. These records led to total revenue for the quarter of $49.9 million, a 20% increase over the same period in 2022, and we produced 10 cents of earnings per diluted share. Our sales force continues to increase productivity and grow orders significantly each quarter, a testament to a great sales force, leadership, and great products. Orders increased 39% year-over-year, and we believe that there is considerable runway for us to continue growing orders into the future. The results we continue to show and the good work we are doing toward reducing the impact opioids have on communities are beginning to be recognized by the broader community, with the latest example being our ranking as the 23rd amongst the top 100 healthcare companies according to the Healthcare Technology Report. To help drive our growth, we introduced three new rehabilitation products in the third quarters. building on our holistic, non-invasive approach to pain management. The new products include Sinex Pro-Cerastic Lumbar Sacral Orthosis, or TLSO, a dual-purpose back brace for the mid and lower spine, Sinex Pro-Wrist, a wrist brace for a broad spectrum of wrist-related pain management, including carpal tunnel syndrome, and the Sinex CryoHeat, a localized cold or hot fluid therapy system for home or hospital use. We continue to focus on profitable growth by adding products to our portfolio in a complementary way that combine with our industry leading prescription strength pain management device, the NexWave. In addition to the impressive results from our profitable pain management division, CMS, or Sinix Monitoring Solutions, continue to move forward in the third quarter in the development of our blood and fluid monitor and our laser-based pulse oximeter, or co-oximeter. We were excited to announce FDA clearance earlier this year for our second-generation blood and fluid volume monitor, an invasive wireless technology targeted to improve patient outcomes with better fluid management in hospital settings. We continue to collect additional data in clinical trials, and Don Gregg will provide further updates on this product in his prepared remarks. We have three additional products in the pipeline in our hospital monitoring division. A laser-based pulse oximeter, NICO is the trade name for it, a monitor for early detection of sepsis, and a non-invasive laser-based monitor of total hemoglobin levels, the HEMOX. Overall, we are making great progress in the patient monitoring division, which we believe will have a game-changing growth potential for the company. Looking ahead, we are making significant progress building on our holistic, non-invasive approach with at-home pain management devices and diversifying with new products. We are rapidly expanding direct sales that is delivering accelerating and high recurring revenue as we continue to execute operationally and strategically. In tandem, we are focused on ramping up our hospital monitoring division, which represents a large and growing market opportunity. We expect consistent growth and strong financial performance for the remainder of 2023, following the double-digit growth we have produced year after year. We also expect an additional catalyst and regulatory milestones in 2023 as we work to execute on our strong pipeline of new products. We look forward to additional updates in the months to come as we build our sales force and execute on growth objectives to improve the quality of life of patients suffering from debilitating pain or illnesses and bring long-term value for our shareholders. With that, I'll turn the call over to Anna Lukczak, our Chief Operating Officer, for a more detailed business update on the Pain Management Division.